Differential impairment of triazolam and zolpidem clearance by ritonavir

Journal of Acquired Immune Deficiency Syndromes

Volumn 24, Issue 2, 2000, Pages 129-136

  Greenblatt, David J ^a   Von Moltke, Lisa L ^a   Harmatz, Jerold S ^a   Durol, Anna Liza B ^a   Daily, Johanna P ^b   Graf, Jennifer A ^a   Mertzanis, Polyxane ^a   Hoffman, Jonathan L ^a   Shader, Richard I ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cytochrome P450 3A; Drug interactions; In vitro metabolism; Ritonavir; Triazolam; Viral protease inhibitors; Zolpidem

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CYTOCHROME P450 3A; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; TRIAZOLAM; ZOLPIDEM;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG MIXTURE; DRUG POTENCY; DRUG TRANSFORMATION; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIVER MICROSOME; NORMAL HUMAN; PRIORITY JOURNAL; RETROVIRUS INFECTION;

EID: 0034209862     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200006010-00007     Document Type: Article

References (48)

1. van Gorp WG, Buckingham SL, eds. Practitioner's guide to the neuropsychiatry of HIV/AIDS. New York: The Guilford Press, 1998.
2. Ochitill H, Dilley J, Kohlwes J. Psychotropic-drug prescribing for hospitalized patients with acquired-immunodeficiency-syndrome. Am J Med 1991;90:601-5.
3. Zisook S, Peterkin J, Goggin KJ, Sledge P, Atkinson JH, Grant I. Treatment of major depression in HIV-seropositive men. HIV Neurobehavioral Research Center Group. J Clin Psychiatry 1998; 59:217-24.
4. Lyketsos CG, Hoover DR, Guccione M, et al. Depressive symptoms over the course of HIV infection before AIDS. Soc Psychiatry Psychiatr Epidemiol 1996;31:212-19.
5. Chesney MA, Folkman S. Psychological impact of HIV disease and implications for intervention. Psychiatr Clin North Am 1994; 17:163-82.
6. Judd FK, Mijch AM. Depression in patients with HIV and AIDS. Aust NZJ Psychiatry 1994;28:642-50.
7. Tseng AL, Foisy MM. Significant interactions with new antiretrovirals and psychotropic drugs. Ann Pharmacother 1999;33:461-73.
8. Chuck SK, Rodvold KA, von Moltke LL, Greenblatt DJ, Shader RI. Pharmacokinetics of protease inhibitors and drug interactions with psychoactive drugs. In Ostrow DG, Kelly JA, eds. Psychosocial and public health impacts of new HIV therapies. New York: Kluwer/Plenum, 1999: 33-60.
9. Barry M, Mulcahy F, Merry C, Gibbons S, Back D. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection, Clin Pharmacokinet 1999;36: 289-304.
10. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998;35:275-91.
11. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Phannacol Toxicol 1998;38: 389-430.
12. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Ann Rev Pharmacol Toxicol 1999;39:1-7.
13. Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995;15:387-98.
14. von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI. Metabolism of drugs by Cytochrome P450 3A isoforms: implications for drug interactions in psychopharmacology. Clin Pharmacokinet 1995;29(Suppl. 1):33-43.
15. Nowell PD, Mazumdar S, Buysse DJ, Dew MA, Reynolds CF, Kupfer DJ. Benzodiazepines and zolpidem for chronic insomnia: a meta-analysis of treatment efficacy. JAMA 1997;278:2170-6.
16. Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Phannacol 1989;36:89-96.
17. von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996;276: 370-9.
18. Pichard L, Gillet G, Bonfils C, Domergue J, Thénot J-P, Maurel P. Oxidative metabolism of zolpidem by human liver cytochrome P450s. Drug Metab Disp 1995;23:1253-62.
19. von Moltke LL, Greenblatt DJ, Granda BW, et al. Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Phannacol 1999;48:89-97.
20. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism in humans: clinical relevance, Clin Pharmacokinet 2000;38:111-80.
21. Greenblatt DJ, Wright CE, von Moltke LL, et al. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clin Phannacol Ther 1998;54: 237-17.
22. Varhe A, Olkkola KT, Neuvonen PJ. Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clin Phannacol Ther 1994;56:601-7.
23. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole. Clin Phannacol Ther 1998;64:661-71.
24. Luurila H, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of zolpidem. Eur J Clin Pharmacol 1998;54:336-40.
25. von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Phannacol 1998;38:106-11.
26. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Harmatz JS, Shader RI. Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994;38:23-31.
27. von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI. Alprazolam metabolism in vitro: studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 1993;47:268-76.
28. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI. Inhibition of triazolam hydroxylation by ketoconazole, itraconazole, hydroxyitraconazole and fluconazole in vitro. Pharm Pharmacol Comm 1998;4:443-5.
29. Scavone JM, Greenblatt DJ, Harmatz JS, Engelhardt N, Shader RI. Pharmacokinetics and pharmacodynamics of diphenhydramine 25 mg in young and elderly volunteers. J Clin Pharmacol 1998;38: 603-9.
30. Durol ALB, Greenblatt DJ. Analysis of zolpidem in human plasma by high-performance liquid chromatography with fluorescence detection: application to single-dose pharmacokinetic studies. J Analyt Toxicol 1997;21:388-92.
31. Granda BW, Giancarlo GM, von Moltke LL, Greenblatt DJ. Analysis of ritonavir in plasma/serum and tissues by high-performance liquid chromatography. J Pharmacol Toxicol Methods 1999;40:235-9.
32. Kroboth PD, McAuley JW, Kroboth FJ, Bertz RJ, Smith RB. Triazolam pharmacokinetics after intravenous, oral and sublingual administration. J Clin Psychopharmacol 1995;15:259-62.
33. Yuan R, Flockhart DA, Balian JD. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. J Clin Pharmacol 1999;39:1109-25.
34. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-58.
35. von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 1998;55:113-22.
36. Greenblatt DJ, von Moltke LL. Can in vitro models predict drug interactions in vivo? A review of methods, problems, and successes. In: Hori W. Drug-drug interactions: analyzing in vitro-in vivo correlations. Southboro, MA: International Business Communications, 1997:2.2.1-2.2.28.
37. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Phannacol Rev 1998; 50:387-412.
38. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998;35:361-90.
39. von Moltke LL, Durol ALB, Duan SX, Greenblatt DJ. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. Eur J Clin Pharmacol 2000;56:259-61.
40. Koudriakova T, Iatsimirskaia E, Utkin I, et al. Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Disp 1998;26:552-61.
41. Silverman R. Mechanism-based enzyme inactivators. Methods Enzymol 1992;249:241-82.
42. Iribame C, Berthou F, Carlhant D, et al. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Disp 1998;26:257-60.
43. Greenblatt DJ, von Moltke LL, Daily JP, Harmatz JS, Shader RI. Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. J Clin Psychopharmacol 1999;19:293-6.
44. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Alprazolamritonavir interaction: implications for product labeling. Clin Pharmacol Ther 2000;67:335-41.
45. Olkkola KT, Palkama VJ, Neuvonen PJ. Ritonavir's role in reducing fentanyl clearance and prolonging its half-life. Anesthesiology 1999;91:681-85.
46. Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther 1999;66:33-9.
47. Gass RJA, Gal J, Fogle PW, Detmar-Hanna D, Gerber JG. Neither dapsone hydroxylation nor cortisol 6 beta-hydroxylation detects the inhibition of CYP3A4 by HIV-1 protease inhibitors. Eur J Clin Phannacol 1998;54:741-7.
48. Frye R, Bertz R, Granneman GR, et al. Effect of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam [abstract A-59]. Presented at the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 1997.